Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
August 02 2023 - 3:01PM
Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical
company developing a new class of complement medicines for patients
with classical complement-mediated autoimmune, neurodegenerative
and ophthalmic disorders, today announced that it has granted an
equity inducement award to Jamie Dananberg, M.D., the company’s
Chief Medical Officer, under the terms of the 2022 Employment
Inducement Award Plan. The equity award was approved on July 22,
2023, effective August 1, 2023, in accordance with Nasdaq Listing
Rule 5635(c)(4).
Dr. Dananberg received an option to purchase
275,000 shares of Annexon common stock. The option carries a
ten-year term and an exercise price per share equal to $3.54, which
was the closing price of Annexon’s common stock on August 1, 2023,
the date of grant, and vests over four years, with 25% of the
shares underlying the option vesting on the first anniversary of
the employee’s employment start date, and an additional 1/48th of
the shares vesting monthly thereafter, subject to continued service
through the applicable vesting dates.
About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical
company seeking to bring game-changing medicines to patients with
classical complement-mediated diseases of the body, brain and eye.
The classical complement pathway within the immune system, when
overactivated, drives a host of autoimmune, neurodegenerative and
ophthalmic diseases. Annexon is advancing a new class of complement
medicines targeting the early classical cascade and all downstream
pathway components that contribute to disease, while selectively
preserving the beneficial immune functions of other complement
pathways. Annexon is rigorously developing a pipeline of
diversified product candidates across multiple mid- to late-stage
clinical trials, with clinical data anticipated throughout 2023 and
beyond.
Investor Contact:
Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From Apr 2024 to May 2024
Annexon (NASDAQ:ANNX)
Historical Stock Chart
From May 2023 to May 2024